InspireMD Q2 FY26 net loss widens 8.9% to $14.32 million; revenue slips 0.4% to $1.77 million
NSPR•Recall costs weigh on results
- The May voluntary U.S. recall of CGuard Prime drove $734,000 in revenue credits.
- Inventory impairment tied to the recall totaled $612,000.
Outlook and restructuring plans
- Management expects to submit a PMA supplement in Q4 2026.
- A post-quarter workforce reduction targets nearly 20% of headcount and $9 million in annualized savings.
Quarterly loss widens as revenue edges lower
- InspireMD posted a net loss of $14.32 million for the quarter ended June 30, 2026, widening 8.9% year over year.
- Revenue slipped 0.4% to $1.77 million, with U.S. revenue at $-351,000 versus $2.12 million internationally.
- Gross loss was $774,000, swinging from gross profit; gross margin fell 61.3 percentage points to -43.7%.
